StreetInsider.com News Articles

Form 10-Q QuidelOrtho Corp For: Jun 28

Fri, 07 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26886731.html

Form 10-Q QuidelOrtho Corp For: Jun 28

Fri, 07 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26886731.html

Quidel Corp (QDEL) Tops Q2 EPS by 17c, Lowers Guidance

Thu, 06 Aug 2026 16:50:08 -0400

Quidel Corp (NASDAQ: QDEL) reported Q2 EPS of $0.13, $0.17 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $630.9 million versus the consensus estimate of $619.53 million.

GUIDANCE:

Quidel Corp sees FY2026 EPS of $0.65-$0.90, versus the consensus of $1.84. Quidel Corp sees FY2026 revenue of $2.52-2.6 billion, versus the consensus of $2.71 billion.

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.

Quidel Corp (QDEL) Tops Q2 EPS by 17c, Lowers Guidance

Thu, 06 Aug 2026 16:50:08 -0400

GUIDANCE:

Quidel Corp sees FY2026 EPS of $0.65-$0.90, versus the consensus of $1.84. Quidel Corp sees FY2026 revenue of $2.52-2.6 billion, versus the consensus of $2.71 billion.

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.

Form 8-K QuidelOrtho Corp For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883849.html

Form 8-K QuidelOrtho Corp For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883849.html

QuidelOrtho Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―

― Excluding China, total revenue grew 6% both as reported and in constant currency ―

― Company updates full-year 2026 financial guidance ―

SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026.

QuidelOrtho Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―

― Excluding China, total revenue grew 6% both as reported and in constant currency ―

― Company updates full-year 2026 financial guidance ―

QuidelOrtho Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―

― Excluding China, total revenue grew 6% both as reported and in constant currency ―

― Company updates full-year 2026 financial guidance ―

QuidelOrtho Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―

― Excluding China, total revenue grew 6% both as reported and in constant currency ―

― Company updates full-year 2026 financial guidance ―

Form SCHEDULE 13G/A QuidelOrtho Corp Filed by: Neuberger Berman Group LLC

Wed, 05 Aug 2026 15:28:00 -0400

si-local-file:///var/storage/secattach/20260805/26873397.html

Form SCHEDULE 13G/A QuidelOrtho Corp Filed by: Neuberger Berman Group LLC

Wed, 05 Aug 2026 15:28:00 -0400

si-local-file:///var/storage/secattach/20260805/26873397.html

QuidelOrtho to Report Second Quarter 2026 Financial Results

Fri, 24 Jul 2026 07:00:00 -0400

SAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026.

QuidelOrtho to Report Second Quarter 2026 Financial Results

Fri, 24 Jul 2026 07:00:00 -0400

QuidelOrtho to Report Second Quarter 2026 Financial Results

Fri, 24 Jul 2026 07:00:00 -0400

QuidelOrtho to Report Second Quarter 2026 Financial Results

Fri, 24 Jul 2026 07:00:00 -0400

Beyond Fentanyl: How the Drug Crisis Is Changing

Thu, 23 Jul 2026 09:21:00 -0400

SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.

Beyond Fentanyl: How the Drug Crisis Is Changing

Thu, 23 Jul 2026 09:21:00 -0400

Beyond Fentanyl: How the Drug Crisis Is Changing

Thu, 23 Jul 2026 09:21:00 -0400

Beyond Fentanyl: How the Drug Crisis Is Changing

Thu, 23 Jul 2026 09:21:00 -0400

Form 4 QuidelOrtho Corp For: Jul 15 Filed by: Young Micah W

Thu, 16 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260716/26779935.html

Form 4 QuidelOrtho Corp For: Jul 15 Filed by: Young Micah W

Thu, 16 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260716/26779935.html

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 19:31:00 -0400

SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr. Young's entering into employment with the

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 19:31:00 -0400

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 19:31:00 -0400